Phytopharm Share Discussion Threads

[hectorp] 21/5/2013 07:59

Goodbuye Phytopharm

[waterloo01] 21/5/2013 07:57

Well read Mrs A and Money. RTO it is.

[moneymachine2] 05/5/2013 03:35

From last RNS: -

After discussions with major shareholders the Board has initiated a review of the strategic options available to the Company which includes the review of a number of merger and acquisition opportunities. Exploratory discussions have been held with a number of parties and further updates will be made as appropriate.

Cash in Bank, huge tax losses, looks good for RTO.

[mrsapeslaptop] 05/5/2013 00:15

cash 1.7p
tax losses £80m, woth another 2 p per share to a company with profits @18% corporate tax rate.
Ftse listing worth £500k via areverse takeover rather than a prospectus (fees would be more than that)

[miss womble] 04/5/2013 11:58

Mrs Apeslaptop How do you calculate the value to be 4p? Good luck

[moneymachine2] 30/4/2013 14:07

volume really picking up now.

[moneymachine2] 30/4/2013 08:33

no wonder, it moves on small buys, on the move again today.Any news or volume and this will fly.

[mrsapeslaptop] 29/4/2013 23:36

o/t ramble.
I first got into bios 30 years ago, when working in pharma, one of the regulatory guys asked me about skypharma. then a tuppeny stock. I looked them up with my accountants eye and thought no.
then within a month a reverse takeover and the shareprice 8 bagged.

This wont do that, however my life is full of fractals at the moment (echoes from the past reappearing).

I think fair value on the co is close to 4p at the moment. I await what transpires with great interest.

[gerhart] 29/4/2013 21:20

From memory, 85% held by three Insts - and I doubt they'll give them away for nout! And last announcement did say some talks had already taken place with regard to possible merger, take over, etc.

[mrsapeslaptop] 29/4/2013 15:24

only 100 punters have more than £200 worth. all held by a few institutions

[ewads] 29/4/2013 15:20

Only 347m shares in issue

[moneymachine2] 29/4/2013 13:16

and up 8% today, this moves on small buys, shares must be held very tightly.

[moneymachine2] 29/4/2013 13:05

a bit of volume today and last week??.

[moneymunch] 07/4/2013 08:33

Healthcare Investment Opportunities joins AIM

05/04/2013 Harriet Russell

HIO has started trading as a public company

Investment scouter Healthcare Investment Opportunities (LON:HIO) has joined London's junior market this morning.

The company completed an additional placing along with the float of 40 million shares at a price of 10p per share, raising gross proceeds worth £4 million. The market capitalisation of the company is expected to be approximately £4.1 million.

The funds raised will be used for working capital whilst the Board seek suitable investments and, where applicable, acquisitions in line with the Company's Investment Policy.

The board has said it intends to use the proceeds for working capital needs as well as for any upcoming acquisitions deemed useful for the company.

The first acquisition will be likely to be a reverse takeover but will be subject to shareholder approval and is expected to be made within six months of admission.

In addition, the board may also consider making other smaller acquisitions or investments although the directors have said they do not intend to create a portfolio of 'unconnected companies'.

The board as a whole, and in particular chairman David Evans are said to have an extensive contact base and a proven record of creating value for investors through building businesses in the healthcare sector via a combination of organic and acquisitive growth.

Examples include Axis Shield, BBI Holdings, DxS, EKF Diagnostics Holdings, Epistem Holdings, Scancell Holdings and Sirigen Group.

Shares were trading at 11.3p today.

[gerhart] 27/3/2013 20:48

I'm delighted I bought in here now when it was panned. I knew I was taking a (big for me) chance but yesterday's announcement is great. Clearly a lot of talking is already under way.

Given the cash, tax credits for losses, main listing, and also importantly the fact that the bulk of the shares are held by a few savvy groups/people then we are assured of a sound deal.

IMHP if your not already in, then now is a great time to get in and not after the MMs hear an announcement first, because then the share price will go up vertical to some level.

Good luck all. G

[geoff80] 26/3/2013 08:35

A speculative buy today.

[topinfo] 26/3/2013 07:28

Leb lol. With all that cash in the bank I dont think so.

After discussions with major shareholders the Board has initiated a review of the strategic options available to the Company which includes the review of a number of merger and acquisition opportunities. Exploratory discussions have been held with a number of parties and further updates will be made as appropriate.

[topinfo] 26/3/2013 07:16

Rns on strategic review. It could just be about to get very interesting from here. Cash in bank now more than mkt cap and huge tax losses. Perfect RTO or takeover tgt IMO.

Extract from todays Rns.

After discussions with major shareholders the Board has initiated a review of the strategic options available to the Company which includes the review of a number of merger and acquisition opportunities. Exploratory discussions have been held with a number of parties and further updates will be made as appropriate.

Notes to Editors

[topinfo] 26/3/2013 07:15

Rns on strategic review. It could just be about to get very interesting from here. Cash in bank now more than mkt cap and huge tax losses. Perfect RTO or takeover tgt IMO.

Extract from todays Rns.

After discussions with major shareholders the Board has initiated a review of the strategic options available to the Company which includes the review of a number of merger and acquisition opportunities. Exploratory discussions have been held with a number of parties and further updates will be made as appropriate.

Notes to Editors

[skinny] 26/3/2013 07:15

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group" or the "Company") today announces an update on the on-going strategic review which was initiated following the announcement of headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease. The update will also be provided to shareholders attending the Company's AGM today.

On the 18th February Phytopharm announced that analysis of the headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy. A full analysis of the complete dataset has now been completed which confirms the initial view that no efficacy was demonstrated in the primary or secondary endpoints measured in the study.

As a result of these findings no further research and development expenditure will be committed and a staff reduction and cost saving programme has been initiated.
After discussions with major shareholders the Board has initiated a review of the strategic options available to the Company which includes the review of a number of merger and acquisition opportunities. Exploratory discussions have been held with a number of parties and further updates will be made as appropriate.

[skinny] 26/3/2013 07:14

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group" or the "Company") today announces an update on the on-going strategic review which was initiated following the announcement of headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease. The update will also be provided to shareholders attending the Company's AGM today.

On the 18th February Phytopharm announced that analysis of the headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy. A full analysis of the complete dataset has now been completed which confirms the initial view that no efficacy was demonstrated in the primary or secondary endpoints measured in the study.

As a result of these findings no further research and development expenditure will be committed and a staff reduction and cost saving programme has been initiated.
After discussions with major shareholders the Board has initiated a review of the strategic options available to the Company which includes the review of a number of merger and acquisition opportunities. Exploratory discussions have been held with a number of parties and further updates will be made as appropriate.